AveXis, Inc.
(NASDAQ : AVXS)

( )
AVXS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.25%80.150.9%$597.90m
CELGCelgene Corporation
0.58%137.501.1%$551.19m
AMGNAmgen Inc.
0.00%181.901.1%$427.51m
BIIBBiogen Inc.
2.18%343.001.2%$376.49m
REGNRegeneron Pharmaceuticals, Inc.
0.00%445.682.7%$321.88m
ALNYAlnylam Pharmaceuticals, Inc
0.00%121.8910.7%$270.07m
VRTXVertex Pharmaceuticals Incorporated
0.00%154.701.9%$225.87m
INCYIncyte Corporation
0.00%116.602.5%$209.70m
ALXNAlexion Pharmaceuticals, Inc.
0.00%140.841.9%$178.28m
ILMNIllumina, Inc.
0.00%206.233.5%$141.08m
EXELExelixis, Inc.
0.45%29.156.5%$134.83m
CLVSClovis Oncology, Inc.
0.00%84.5816.5%$131.34m
BLUEBluebird Bio, Inc.
0.14%143.5017.3%$122.17m
SRPTSarepta Therapeutics, Inc.
0.00%50.7316.9%$110.70m
BMRNBioMarin Pharmaceutical Inc.
0.00%94.664.4%$104.77m

Company Profile

AveXis, Inc. operates as a clinical-stage gene therapy company that engages in the research and development of technology specifically for neurological genetic disease treatment. Its proprietary gene therapy candidate, AVXS-101 has been granted orphan drug designation for the treatment of all types of spinal muscular atrophy and fast track designation for the treatment of spinal muscular atrophy type 1. The company was founded by John D. Harkey, Jr. in 2010 and is headquartered in Chicago, IL.